AlphaQuest LLC Lowers Stock Position in Medpace Holdings, Inc. $MEDP

AlphaQuest LLC trimmed its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 78.7% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 484 shares of the company’s stock after selling 1,785 shares during the period. AlphaQuest LLC’s holdings in Medpace were worth $249,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Fifth Third Wealth Advisors LLC raised its position in Medpace by 2.6% in the third quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the period. Portside Wealth Group LLC grew its stake in shares of Medpace by 2.5% in the second quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after buying an additional 27 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its stake in shares of Medpace by 35.1% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares in the last quarter. M&T Bank Corp raised its holdings in shares of Medpace by 3.4% in the 2nd quarter. M&T Bank Corp now owns 939 shares of the company’s stock valued at $295,000 after buying an additional 31 shares during the period. Finally, Front Row Advisors LLC lifted its stake in Medpace by 0.4% during the 2nd quarter. Front Row Advisors LLC now owns 9,441 shares of the company’s stock worth $2,963,000 after acquiring an additional 35 shares in the last quarter. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Wall Street Analyst Weigh In

MEDP has been the subject of several research reports. Mizuho set a $660.00 target price on Medpace in a research report on Friday, January 9th. BMO Capital Markets initiated coverage on shares of Medpace in a report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective for the company. Zacks Research downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Monday, January 12th. Barclays increased their target price on shares of Medpace from $485.00 to $525.00 and gave the stock an “underweight” rating in a report on Monday, December 15th. Finally, TD Cowen restated a “sell” rating on shares of Medpace in a research note on Friday, October 24th. Two analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Medpace has a consensus rating of “Reduce” and a consensus price target of $491.27.

Insider Buying and Selling at Medpace

In other Medpace news, VP Susan E. Burwig sold 20,000 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO August J. Troendle sold 59,025 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $607.78, for a total value of $35,874,214.50. Following the sale, the chief executive officer directly owned 774,602 shares of the company’s stock, valued at $470,787,603.56. This trade represents a 7.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 302,192 shares of company stock worth $182,019,762 in the last three months. 20.30% of the stock is currently owned by corporate insiders.

Medpace Stock Down 2.2%

Shares of Medpace stock opened at $530.35 on Tuesday. Medpace Holdings, Inc. has a 52-week low of $250.05 and a 52-week high of $628.92. The company has a market capitalization of $14.94 billion, a P/E ratio of 37.09, a P/E/G ratio of 1.82 and a beta of 1.42. The company has a 50 day moving average of $578.30 and a 200 day moving average of $539.57.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Monday, February 9th. The company reported $4.67 EPS for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The company had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a net margin of 18.36% and a return on equity of 91.88%. The company’s quarterly revenue was up 32.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.